Is NMN Legal Again? The 2025 FDA Reversal and What It Means for the NDI Pathway

Whether NMN is “legal” as a US dietary supplement is not a yes-or-no question — it is a regulatory status under active dispute. The FDA’s 2022 application of the drug-preclusion clause at FD&C Act 201(ff)(3)(B), the 2023 NPA and Alliance for Natural Health legal response, and the agency’s subsequent adjustments through 2025 have left NMN on shelves but in regulatory limbo. This article walks through the legal framework, the actual documents, and what the most recent developments do and do not change.

Why is “Is NMN legal?” even a question?

Most dietary ingredients sold in the United States move through one of two paths under the Dietary Supplement Health and Education Act of 1994 (DSHEA): an “old dietary ingredient” grandfathered as marketed before October 15, 1994, or a “new dietary ingredient” (NDI) that triggers a notification under 21 USC 350b at least 75 days before introduction into commerce. NMN is squarely in the NDI camp. It was not in the supplement marketplace before 1994, so any lawful US supplement marketing must satisfy NDI requirements.

The complication is a separate provision of the Food, Drug, and Cosmetic Act. Section 201(ff)(3)(B) excludes from the dietary-supplement definition any article that was first “authorized for investigation as a new drug” (and for which “substantial clinical investigations have been instituted and...made public”) before being marketed as a food or supplement. This is the drug-preclusion clause. It is the same provision that has been invoked against CBD, NAC at various points, and several other compounds — and it is the heart of the NMN dispute.

What did the FDA actually say in 2022?

In late 2022, FDA issued response letters to NDI notifications for NMN, including a widely circulated letter to Inner Mountain Botanicals. The agency declined to acknowledge the NDI submission on the grounds that NMN had been authorized for investigation as a new drug, and that substantial public investigations were ongoing — pointing to the IND-stage candidate MIB-626 (an NMN formulation being studied by MetroBiotech, founded around the lab of Harvard researcher David Sinclair). On the FDA’s reading, that triggered the 201(ff)(3)(B) exclusion and meant NMN could not be lawfully marketed as a dietary supplement under DSHEA.

Several details matter for understanding the dispute:

• The letter was a status determination, not a recall. FDA did not seize products, did not issue a public consumer warning, and did not initiate enforcement actions against retailers. The letter rejected the regulatory pathway, not the shelf presence.
• The drug authorization predates major supplement marketing — that is the FDA’s claim.The investigational drug authorization for MIB-626 was issued before the bulk of NMN’s supplement-channel growth, and FDA argued the “substantial clinical investigations made public” threshold was met by the time of NDI filings.
• Industry disputed every element. Trade groups challenged whether the IND authorization timing applied to the chemical NMN broadly or only to a specific MIB-626 formulation, whether public-investigation thresholds were met, and whether the agency had applied 201(ff)(3)(B) consistently across comparable ingredients.

The NDI Master Directory record

FDA’s NDI Master Directory is the public record of submitted notifications and the agency’s response. Each NDI submission receives a number; the agency’s response — acknowledged, objected, or non-acknowledged on procedural or substantive grounds — is published. For NMN, the directory shows multiple submissions and the relevant letters. Anyone tracking the regulatory status through changes should treat the Master Directory entries plus the FDA dietary supplements ingredient advisory list as primary sources, not press releases.

What was the 2023 NPA and ANH legal challenge?

The Natural Products Association (NPA) and the Alliance for Natural Health (ANH) — two of the most active trade and advocacy organizations in the supplement industry — pushed back through multiple channels in 2023. NPA filed a citizen petition with FDA formally requesting the agency reverse its NMN determination, and ANH issued public legal analyses challenging the agency’s application of 201(ff)(3)(B). The arguments clustered around four themes:

1. Authorization timing.Did the IND for MIB-626 actually predate substantial NMN supplement marketing? Petitioners argued NMN had been sold in the US supplement channel earlier than the FDA timeline acknowledged, and that the “authorization for investigation” language should attach to the specific drug candidate, not the underlying molecule.
2. Substantial public investigations threshold. The statute requires investigations that are both substantial and publicly known. Petitioners argued the early MIB-626 work did not meet either prong at the relevant decision point.
3. Agency inconsistency. If 201(ff)(3)(B) is read as broadly as the NMN letters suggest, several other ingredients on the market today would also be excluded. Petitioners argued the agency was applying the clause selectively.
4. Procedural standing. NDI letters are not adjudicative rulemaking with notice-and-comment. Petitioners argued that an interpretation with this much industry impact required a more formal regulatory process, not single-firm response letters.

FDA has the discretion to grant, deny, or sit on a citizen petition. As a matter of practice, agencies often respond slowly — and the substantive position can shift in subsequent correspondence rather than through formal denial.

What did the “2025 FDA reversal” actually involve?

Headlines describing a clean “FDA reversal” on NMN compress a more complicated picture. Through publication date, the most accurate description of the agency’s posture is this: FDA has not issued a final rulemaking rescinding the 2022 determination, but it has stepped back from active enforcement and has revisited the analysis in subsequent correspondence with industry. Several pieces moved together:

• Enforcement posture. FDA has not pursued seizure or warning-letter actions against NMN sellers operating under dietary-supplement framing. That is enforcement discretion, not legal endorsement.
• Follow-up FDA correspondence. The agency has engaged with NPA and ANH submissions and, in some published letters, acknowledged areas where the 2022 reasoning needs refinement.
• Investigational drug status of MIB-626.The MetroBiotech program has continued to publish trial data, which, depending on framing, either reinforces the drug-preclusion claim or weakens it (because public trial activity is exactly what the “substantial public investigation” clause references).
• Practical retail status. NMN remained in retail circulation throughout the dispute. Major supplement chains, direct-to-consumer brands, and pharmacy aisles continued to stock NMN products.

How does the NDI pathway work, and where does NMN fit?

The NDI notification process is the front door for any ingredient that was not in the US supplement marketplace before October 15, 1994. The mechanics are statutory:

1. The manufacturer or distributor files a notification with FDA at least 75 days before introducing the ingredient into interstate commerce.
2. The notification must include the identity of the ingredient, the conditions of use, and the safety basis under which the notifier expects the ingredient to be reasonably safe.
3. FDA reviews and either acknowledges (without objection) or objects to the notification on substantive grounds. Acknowledgment is not approval — DSHEA does not require pre-market approval for supplements.
4. Non-acknowledgment with substantive objection effectively challenges the legal basis for marketing.

FDA’s NMN response in 2022 was a non-acknowledgment letter citing 201(ff)(3)(B) as the substantive ground. That is unusual. Most NDI objections cite safety data gaps; an exclusion-clause objection means the ingredient cannot qualify as a supplement at all, regardless of safety profile. That distinction is what elevated the dispute from a single-firm filing question to an industry-wide regulatory question.

Comparison: how NMN’s status differs from related compounds

Comparing NMN to other NAD+-related ingredients illustrates how narrow the regulatory question is. Each row below summarizes the public regulatory posture; treat it as orientation, not compliance counsel:

• Nicotinamide riboside (NR): NDI notifications acknowledged. Marketed as a dietary supplement without a 201(ff)(3)(B) challenge of comparable scope.
• Niacin (nicotinic acid): Long-grandfathered, dual-status ingredient (food, supplement, and prescription drug at higher doses).
• Nicotinamide (NAM): Long-marketed; covered in our review of NAM versus NR versus NMN. Generally accepted as a dietary ingredient.
• NMN: NDI notifications non-acknowledged on 201(ff)(3)(B) grounds in 2022; status contested through 2025.
• MIB-626 (an NMN formulation): Investigational drug, MetroBiotech sponsor. Public clinical trial activity is part of the regulatory record cited by FDA.

The pattern matters: the same molecular family can occupy different legal lanes depending on which entity files what type of submission first, and the clauses that carve up those lanes are technical.

How does NMN compare to other compounds with parallel drug and supplement status?

The drug-versus-supplement question is not unique to NMN. Several molecules sit in dual investigational-drug-and-supplement territory, and each case turns on the precise sequence of drug authorization, supplement marketing, and the “substantial public investigations” threshold:

• NAC (N-acetylcysteine). FDA in 2020 took the position that NAC was excluded from supplement status under 201(ff)(3)(B) because it had been approved as a drug in 1963. Industry response, including NPA citizen petitions, eventually led to a 2022 enforcement-discretion guidance allowing NAC to remain in the supplement marketplace pending rulemaking. The NMN dispute follows a similar template: an exclusion-clause ruling, industry pushback, and a softening of enforcement that stops short of rescinding the legal interpretation.
• CBD. FDA has consistently held that CBD is excluded from supplement status because it was first approved as a drug (Epidiolex). Unlike NAC and NMN, CBD enforcement has been tighter, particularly for products making disease claims.
• MIB-626 versus NMN.The MetroBiotech program investigates a specific NMN formulation under an IND. The regulatory framing question is whether the IND attaches to the molecule generally or to the specific drug-product formulation. FDA’s 2022 letters took the broader reading; industry argues for the narrower one.

What does the current status mean for retail buyers?

Retail availability of NMN in the US has not been disrupted by the regulatory dispute. Major chains, online retailers, and DTC brands continue to sell NMN-labeled products under standard dietary-supplement framing. That practical reality does not change the underlying legal contention — but it does mean buyers encounter NMN on shelves regardless of the FDA NDI position.

From a consumer-information standpoint, the practical implications cluster in three places:

• Quality variation is a separate issue from legal status. NMN purity, third-party testing, and label accuracy are independent of the regulatory pathway. A product can be sold under contested supplement framing and still be well-manufactured — or poorly manufactured — and the FDA NDI dispute does not address either case.
• Marketing claims remain restricted by DSHEA structure. Even where NMN is sold as a supplement, structure-function claims must avoid drug-claim territory. Disease prevention or treatment claims convert any supplement into an unapproved drug in FDA’s eyes.
• Status can change without warning.A future rulemaking, court decision, or enforcement-policy update could shift NMN’s availability. Anyone whose purchasing or health regimen depends on continued availability should track the FDA NDI Master Directory and major industry filings.

What does the situation mean for manufacturers and retailers?

For supply-side participants, the regulatory ambiguity translates to specific compliance considerations. None of the following is legal advice — but each maps to a question that has surfaced in the public record of the dispute:

1. NDI filings remain a live question. Whether to file or refile NDI notifications under current FDA posture is a compliance call. Refiling can produce updated agency correspondence — useful for the public record — or trigger another non-acknowledgment.
2. Labeling discipline matters more, not less. Marketing copy that veers into disease-treatment territory can convert a contested supplement into an unapproved drug under 21 USC 355(a), which is a separate and clearer violation than the 201(ff)(3)(B) status question.
3. Documentation of supply chain and quality. Independent of the supplement-versus-drug debate, cGMP requirements (21 CFR 111) for dietary supplements continue to apply to anything sold under the supplement framework.
4. Ongoing engagement with trade groups. NPA and ANH have been the primary public-record advocates for the industry position. Their published filings are useful primary sources.

How can I track the actual current status?

Because the situation is genuinely fluid, the most useful approach is to bookmark primary sources rather than rely on summaries:

• FDA NDI Master Directory — searchable record of NDI submissions and FDA responses. This is the cleanest place to see whether new NMN notifications have been filed and how they were handled.
• FDA Dietary Supplement Ingredient Advisory List — public-facing list of ingredients FDA has flagged as not lawfully marketed as supplements. Inclusion or removal of NMN here is a clear status signal.
• NPA and ANH press releases and citizen-petition dockets — the public record of trade-group activity, including any new petitions or court filings.
• ClinicalTrials.gov entries for MIB-626and other NMN-based investigational drug programs — relevant because ongoing “substantial public investigations” are part of the 201(ff)(3)(B) factual basis.
• Federal Register notices — any formal rulemaking, guidance issuance, or proposed regulation on the NMN status would appear here first.

The honest summary

Through publication, NMN occupies a contested space in US regulation. The FDA’s 2022 application of FD&C Act 201(ff)(3)(B) — citing the IND-stage MIB-626 program — has not been formally rescinded. The NPA and ANH legal and citizen-petition response has not produced a clean reversal. Enforcement discretion has allowed continued retail availability, but availability is not the same as a clear legal pathway. Anyone reading “NMN is fully legal again” or, conversely, “NMN is banned” is reading a simplification of a more unsettled record.

For consumers, the practical state is: NMN remains widely available in the US, sold under dietary-supplement framing, and the underlying legal question of whether it lawfully qualifies as a supplement is unresolved. For manufacturers, the compliance environment is ambiguous in ways that reward conservative labeling, transparent quality testing, and ongoing engagement with the agency through NDI and citizen-petition channels. For researchers and clinicians, NMN’s investigational-drug and supplement-channel status are simultaneous, not contradictory — the same molecule can be studied under IND and sold under DSHEA, with the regulatory framing depending on who files what under which provision.

The cleanest path to staying current is to read the primary sources — the FDA NDI Master Directory, the Dietary Supplement Ingredient Advisory List, NPA and ANH filings, and any Federal Register notice on the topic — rather than depend on news summaries. The status of NMN under US law is a live legal question, and it is being answered piece by piece in documents most casual readers never see.